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Abstract
Background—Although biological markers of women’s exposure to semen from vaginal 
intercourse have been developed as surrogates for risk of infection or probability of pregnancy, 
data on their persistence time and clearance are limited.
Study Design—During 2006–2008, 52 couples were enrolled for three 14-day cycles of 
abstinence from vaginal sex during which women were exposed in the clinic to a specific quantity 
(10, 100 or 1000 μL) of their partner’s semen. Vaginal swabs were collected before and at 1, 6, 12, 
24, 48, 72 and 144 h after exposure for testing for prostate-specific antigen (PSA) and Y-
chromosome DNA (Yc DNA).
Results—Immediately after exposure to 1000 μL of semen, the predicted sensitivity of being 
PSA positive was 0.96; this decreased to 0.65, 0.44, 0.21 and 0.07 at 6, 12, 24 and 48 h, 
respectively. Corresponding predicted sensitivity of being Yc DNA positive was 0.72 immediately 
postexposure; this increased to 0.76 at 1 h postexposure and then decreased to 0.60 (at 6 h), 0.63 
(at 12 h), 0.49 (at 24 h), 0.21 (at 48 h), 0.17 (at 72 h) and 0.12 (at 144 h).
Conclusions—Overall findings suggest that PSA may be more consistent as a marker of very 
recent exposure and that Yc DNA is more likely to be detected in the vagina after 12 h 
postexposure compared to PSA.
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1. Introduction
Traditionally, biologic and behavioral studies related to sex and contraceptive efficacy rely 
on self-reports of sexual behavior and condom use, which are susceptible to bias [1–3]. 
Difficulties in accurately assessing condom and microbicide effectiveness have led to the 
development of objective markers of exposure to semen as surrogate outcomes for risk of 
infection or probability of pregnancy [4]. Prostate-specific antigen (PSA), the most widely 
used and extensively characterized biomarker of semen exposure, occurs at high 
concentrations in seminal fluid. Although PSA can occur in other body fluids, 
concentrations of endogenous PSA identified in vaginal fluid are too low to be misclassified 
as resulting from semen exposure [5,6]. The detection of PSA in vaginal fluid in 
concentrations ≥1 ng/mL is indicative of exposure to semen exposure within the previous 48 
h [7–10]. A second biomarker involves detecting Y-chromosome DNA (Yc DNA) fragments 
from spermatozoa in vaginal fluid. Using a polymerase chain reaction (PCR) assay, Yc DNA 
has been found in vaginal swabs collected up to 15 days after unprotected intercourse, with a 
half-life for clearance of 3.8 days [11,12].
Each of the two biomarkers could be preferable in different research studies depending on 
the clearance time desired and whether the focus is on the probability of pregnancy or 
infection. That is, because PSA is expressed independently of spermatozoa, it remains useful 
as a measure of risk of infection (but not of pregnancy) from exposure to semen from 
vasectomized males or those with low sperm counts [13]. In contrast, Yc DNA is only 
detected when spermatozoa are present, which makes it a useful measure of probability of 
pregnancy. Sexually transmitted infection (STI) risk, though, may be missed if the swab for 
Yc DNA testing captures only preejaculate or seminal fluid without any spermatozoa.
Our primary objective was to characterize and compare the rates of decay of PSA and Yc 
DNA in vaginal fluid specimens and the corresponding sensitivity of specimens being PSA 
and Yc DNA positive at specific times after women were exposed to varying amounts of 
semen. Our secondary objective was to assess agreement between PSA and Yc DNA at these 
intervals. Because of the potential for wide variations in women’s baseline vaginal 
environment, couples' sexual practices and other factors that might compromise such 
comparisons, the best experimental conditions for comparing PSA and Yc DNA would 
involve measuring these biomarkers in the same samples of vaginal fluid. Accordingly, we 
measured PSA and Yc DNA from the same vaginal swab collected after known quantities of 
semen exposure and known timing since exposure.
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2. Materials and methods
2.1. Study population
The study enrolled 52 couples who met the following inclusion criteria: >18 years of age; in 
a mutually monogamous, heterosexual relationship for ≥ 1 year; using effective nonbarrier 
method of birth control or intending to conceive; willing to abstain from intercourse during 
three 2-week “study cycles”; and not enrolled in a full-time undergraduate program. 
Additionally, female partners were experienced with tampon use and had regular menstrual 
periods. Couples were excluded if they reported using condoms >50% of the time in the past 
year; a history of sexually transmitted disease in the past 2 years; or a history of emotional, 
sexual or physical abuse within the relationship.
2.2. Study design
After an initial enrollment visit, during which female partners were trained on self-collection 
of vaginal swabs, each couple contributed three 14-day study cycles of abstinence. Study 
cycles were scheduled to begin just after the female partner completed her menstrual cycle. 
On day 8 of each study cycle, male partners self-collected semen samples a maximum of 1 h 
before female partners presented to the study clinic for semen exposure. At the clinic, a 
clinician used an artificial insemination catheter to deposit a specific quantity (10, 100 or 
1000 μL depending on the study cycle) of the male partner’s semen into the woman’s 
vagina. These quantities were selected to be consistent with past research [9,10]. The highest 
quantity used was about one third of a typical volume of ejaculate [14], while the lower 
semen amounts might be similar to the magnitude of an exposure from a condom 
malfunction. In most cases, the order of exposures was sequential from lowest to highest. 
We used an intrauterine catheter (MedGyn Products, Inc.; Addison, IL, USA) without a 
speculum to introduce the semen sample into the vagina without making any special effort 
for its even distribution. Participants did not ambulate before the first swab collection 
(immediately after exposure), but resumed usual activities before subsequent swab 
collection. Female partners self-collected vaginal fluid specimens using a double-headed 
swab (Starswab II; Starplex Scientific, Cleveland, TN, USA) before and immediately after 
semen exposure and at 1, 6, 12, 24, 48, 72 and 144 h postexposure.
Participants completed detailed daily diaries during the 14-day study cycles. Diaries asked 
about vaginal intercourse, condom use, oral sex, anal sex, use of sex toys and use of vaginal 
products. Participants were counseled extensively on the importance of providing valid self-
reports, and they were advised that they would still receive the modest study reimbursement 
for study participation even if they reported deviating from study procedures such as 
abstinence.
Institutional review boards at The Johns Hopkins University (JHU) School of Medicine and 
US Centers for Disease Control and Prevention (CDC) approved the study.
2.3. Laboratory methods
Immediately following sample collection, all swabs were placed in a resealable bag with two 
dessicants, and swabs were stored at room temperature until processing. The double-headed 
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swabs were rehydrated in 1 mL of phosphate-buffered saline (PBS) for 20 min. Following 
rehydration, the samples were centrifuged for 5 min at 8000 rpm, and all of the supernatant 
except for 100 μL was removed and frozen for later PSA testing. The remaining pellet was 
processed for Yc DNA at JHU using a differential extraction protocol and was tested by 
real-time PCR on the LightCycler v1.2 system (Roche Diagnostics, Indianapolis, IN, USA) 
as previously described [15]. The semen was not processed. In the first cycle, presence of 
sperm was verified by microscopy, but we did not perform semen analysis or sperm counts.
Frozen specimens packaged on dry ice were sent via overnight delivery to the CDC 
laboratory. Upon their receipt, specimens were stored at −80°C until testing, at which point 
they were allowed to sit at room temperature (68°C to 77°C) until visibly thawed 
(approximately 10 min). A technician vortexed the thawed specimens (in cryotubes) for 3–5 
s and pipetted 200 μL of the specimen into a sample cup to test with the Abbott Architect 
Total PSA assay (Abbott Diagnostics, Abbott Park, IL, USA). Samples exceeding the upper 
limit of quantification of the assay (100 ng of PSA per mL) were diluted with PBS and 
retested in order to quantify the concentrations. The lower limit of detection for Yc DNA is 
10 copies, and there is no upper limit because the assay is not saturable.
2.4. Statistical analysis
We calculated and compared the sensitivity of vaginal fluid specimens being PSA and Yc 
DNA positive at specific times over the course of 6 days after women were exposed to 
varying amounts of their partner’s semen. The natural logarithm transformation was used for 
all longitudinal modeling of quantitative values of PSA and Yc DNA. To create categorical 
outcomes for the two biomarkers, a positive PSA result was defined as ≥1 ng/mL [10] and a 
positive Yc DNA result was defined as >0 (detection of any Yc DNA).
Quantitative values of each biomarker were plotted against scheduled time for self-sampling 
following semen exposure (separately for the three deposited amounts of semen) using a 
linear mixed-effects model to account for repeated measurements. Each plot was depicted 
with a fitted curve and, to help visually assess the fit of the curve, a nonparametric smoothed 
spline curve. Models were fitted for each biomarker and each quantity of semen for the 0–6-
day interval following exposure to semen (144-h models). Additionally, because nonstudy 
semen exposures were considered more likely to occur later in the study cycle (when 
couples might have more difficulty continuing to abstain from vaginal sex), models also 
were constructed for the shorter interval of 0–3 days postexposure (72-h models). Although 
initial PSA and Yc DNA concentrations were determined for each cycle, these data were not 
used in the calculation of the decay curves.
Sensitivity analyses were conducted to evaluate the effect of each of the following: (a) 
participants who failed to provide at least 1000 μL of semen for the study cycle requiring 
this amount (n=4 couples); (b) study cycles in which participants reported failure to adhere 
to abstinence from vaginal sex (n=1 couple for the 10-μL cycle, n=2 couples for the 100-μL 
cycle, n=4 couples for the 1000-μL cycle); (c) study cycles that were characterized by 
positive biomarker values (Yc DNA and/or PSA) for swabs collected immediately before 
semen exposure (n=7 couples for the 10-μL cycle, n=8 couples for the 100-μL cycle, n=11 
couples for the 1000-μL cycle) and (d) observations with missing values for the exact time 
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since exposure (n=1 couple for the 10-μL cycle, n=2 couples for the 100-μL cycle, n=2 
couples for the 1000-μL cycle). To determine the effect of differing amounts of semen 
deposited, a continuous covariate for the actual amount was added to the 1000-μL mixed-
effects models. For failure to adhere to abstinence, we both excluded observations 
accompanied by self-reported vaginal sex and included them in main models with a binary 
covariate indicating self-reported vaginal sex. Similarly, for study cycles with positive values 
for Yc DNA or PSA immediately before semen exposure, we both excluded these cycles and 
included them in main models with a binary covariate indicating positivity for either 
biomarker. Finally, to address the issue of missing values for self-reported time since 
exposure, we added a binary covariate indicating this, and we fit a model that used self-
reported time of swab collection when they were available and imputed prescribed collection 
times when these data were not available.
We calculated the predicted sensitivities for positive PSA and Yc DNA results (and the 
difference between the two) at each time point with 95% confidence intervals (CIs) using 
generalized linear mixed-effects models with a logit link function.
3. Results
The decay in biomarker values over time since exposure to semen is presented in Fig. 1 
[log(PSA)], Fig. 2 [log(Yc DNA)] and Table 1. Both the PSA and Yc DNA data were 
heavily skewed, especially for time points closest to exposure. The fitted postexposure 
baseline values of biomarker concentration (i.e., the intercepts of the fitted curves) tended to 
increase with the amount of semen deposited; however, postexposure baseline values for the 
Yc DNA models were similar for the 100-μL and 1000-μL exposures. For both biomarkers, 
regardless of truncation, the rates of decay tended to be lower in the 10-μL models and 
similar in the 100-μL and 1000-μL models. The curves better fit the data in the 72-h models, 
as evident by the differences in the smoothed curves, as compared to the 144-h models, 
which were influenced by outliers (e.g., see dispersion of the PSA data for 100 μL at 144 h 
postexposure).
Predicted sensitivities for positive PSA and Yc DNA results at each time point are presented 
in Table 2 and depicted in Fig. 3. For 1000 μL, the largest amount of exposure in this study, 
the sensitivity of being PSA positive, which began at 0.96 immediately after exposure, 
decreased to 0.44, 0.21 and 0.07 within 12, 24 and 48 h, respectively. At 48 h, which has 
been considered to constitute the end of the window for PSA positivity, the highest 
sensitivity detected was 0.07. At 144 h, the sensitivity of being PSA positive was 0.09, 
which represented an unexpected increase from 0.07 at 72 h.
The sensitivity of being Yc DNA positive with a 1000-μL exposure, which was 0.72 
immediately post-exposure, increased after 1 h to 0.76, after which it fluctuated and then 
decreased to 0.49, 0.21, 0.17, and 0.12 at 24, 48, 72 and 144 h, respectively. At 144 h, which 
is typically considered to be within the window for Yc DNA positivity, the highest 
sensitivity that is consistent with our results was 0.12.
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Immediately after exposure, the two biomarkers had similar sensitivities of detecting semen 
in the 10-μL semen cycle and slightly higher sensitivities of detecting PSA than Yc DNA in 
the 100- and 1000-μL semen cycles (Table 2). From 1 to 12 h after exposure in the three 
cycles, the sensitivities of detecting semen were either similar or higher for Yc DNA in all 
three cycles. For 24–48 h after exposure, the sensitivity of detecting semen for Yc DNA was 
significantly higher for all three cycles. By 72 and 144 h, the detected semen levels were 
detected at slightly higher frequency for Yc DNA, but this difference was not statistically 
significant.
3.1. Sensitivity analyses
Among the 1000-μL semen cycles, the decay curve fitting was not appreciably influenced by 
the few cases in which the exposure volume was actually less than 1000 μL (all parameter 
changes were <10%).
The covariate for self-reported vaginal sex during the study was statistically significant for 
the two models for PSA after exposure to 1000 μL of semen; however, lack of significant 
interaction with time since exposure indicated that the rate of decay was unaffected. When 
we removed self-reported exposures from the models, no parameters changed >10%, other 
than the postexposure baseline values, which increased in the 144-h PSA models after 1000 
μL of semen exposure and in the 72- and 144-h Yc DNA models after 10 μL of semen 
exposure.
The covariate for being preexposure positive was significant only in the 144-h model after 
10 μL of semen exposure for PSA; again, lack of significant interaction with time since 
exposure showed that the rate of decay was not significantly affected. Nevertheless, when 
we removed all preexposure positive study cycles from the models, the rate of decay in the 
144-h model after 100 μL of semen exposure for PSA became more extreme and that of the 
144-h model after 10 μL of semen exposure for Yc DNA became less extreme. Nearly all 
fitted postexposure baseline values decreased by >10% when we excluded preexposure 
positive cycles, which, by definition, began with higher values of PSA and/or Yc DNA.
Covariates representing missing values for self-reported time since exposure were 
nonsignificant in all models, and the fitted curves that used self-reported swab collection 
times were not appreciably different from those that included imputed times.
4. Discussion
In our study, when women were exposed to the larger volumes of semen (100 or 1000 μL), 
PSA was consistently detected immediately postexposure, frequently detected at 1 h pos-
exposure, less consistently detected at later times and only rarely detected by 48 h pos-
exposure. Yc DNA positivity declined more slowly but nevertheless was rarely detected by 
48–144 h after exposure to 10, 100 or 1000 μL of semen. PSA was detected more often than 
Yc DNA immediately after exposure, Yc DNA was detected more frequently during 1–24 h 
after exposure, and the detection of the two biomarkers did not differ at 72 and 144 h after 
exposure.
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For each biomarker, rates of decay were similar for 100-μL and 1000-μL exposures but not 
for the 10-μL exposure. We consider the 10-μL exposure to be different from higher doses in 
several important ways. First, 10 μL corresponds to less than a drop of semen, which easily 
could be missed by a vaginal swab even if specimen collection occurred immediately after 
exposure. Furthermore, if the sample had not dispersed within the vagina, the initial swabs 
could have removed most of the sample. The multiple swab collections also could have 
substantially decreased the volume of semen present at subsequent time points. The low 
predicted sensitivities of biomarker positivity following exposure to 10 μL of semen suggest 
that, for condom failures resulting in only minute exposures to semen, PSA and Yc DNA 
would be detectable only inconsistently. However, the probability of pregnancy or STI from 
these low levels of exposure might be unlikely [16].
The present findings differ somewhat from previous studies of the decay rates of the two 
biomarkers. Two controlled trials using a similar protocol of depositing specific quantities of 
semen from the woman’s male partner into her vagina found higher sensitivities of detecting 
PSA immediately following exposure (100% and 82%–98% [9]) but then a quicker 
clearance, with PSA cleared from almost all specimens (97%–99%) collected 48 h after 
exposure [10]. The two prior trials used a larger (1-mL capacity) swab that has been shown 
in vitro to yield significantly higher mean concentrations of PSA (3–185 times higher 
depending on the duration of freezer storage before testing) than the swab used in the 
present study [17]. Also, the concentrations of PSA in the present study could have been 
further diluted given differences between studies in extraction processes.
An earlier study of Yc DNA, in which women were instructed to self-swab at regular 
intervals after having an act of unprotected sex with their male partner, found higher 
sensitivities of Yc DNA among nonmenstruating women: Yc DNA was detected in 87%, 
18% and 13% of specimens collected at 1, 5 and 7 days following exposure [18]. Similarly, a 
second study, in which women self-swabbed following an unprotected act, found mean 
concentrations of Yc DNA that were substantially higher than those in the present study 
[11]. These differences in Yc DNA findings might be explained by the use of unprotected 
sex as the source of exposure in the earlier studies (rather than controlled applications of 
semen by a clinician), which might have resulted in exposure to higher quantities of semen 
or local changes induced by sexual activity, such as lubrication or blood flow, which then 
influenced biomarker persistence or detection.
To our knowledge, no other published clinical studies with known levels of semen exposure 
have assessed the level of agreement between the two biomarkers or have compared their 
rates of decay. In an earlier study, 264 women attending a reproductive health clinic in 
Central African Republic, who reported being sexually active, had vaginal washings 
collected for testing for PSA and Yc DNA [19]. The two biomarkers agreed in 214 cases 
(81%). In the remaining 50 cases, Yc-DNA was positive and PSA negative, which could be 
expected since Yc-DNA persists longer than PSA.
Interestingly, we found that the predicted sensitivities of Yc DNA positivity sometimes 
increased from one time point to the next (even from immediately postexposure to 1 h 
postexposure, a time interval which is unlikely to have been influenced by new, nonstudy 
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semen exposures). Similarly, it was not uncommon for a Yc DNA-negative swab to be 
followed by a Yc DNA-positive swab within a single study cycle. Thus, assuming the 
absence of new exposures, women could test positive for Yc DNA after having already 
tested negative. Overall, the Yc DNA results appear to have more inconsistency than the 
PSA results, which may reflect a “hit or miss” probability of the swab encountering sperm 
containing the DNA. In contrast, seminal fluid might disperse more evenly or widely in 
vaginal fluid and, thus, be more consistently detected. Unexpected increases in Yc DNA 
concentrations also could have occurred if inhibitors of the PCR were present in semen and 
these diluted over time in the vagina.
Deviations occurred when participants were unable to generate a full 1000 μL of semen for 
that cycle, reported having engaged in vaginal sex during study cycles, were positive for 
PSA and/or Yc DNA before being exposed to semen in the clinic or failed to record time of 
swab collection. Our sensitivity analyses indicated that none of these factors on its own was 
likely to have influenced the interpretation of our findings. Nevertheless, we did not examine 
how these factors might have interacted to affect the study findings.
Although participants were counseled extensively on the importance of providing accurate 
self-reports (e.g., of sexual activity and swab collection times), the potential for social 
desirability bias and misrepresentation exists. Statistical outliers reflecting high biomarker 
levels at 24-, 72- and 144-h collection points led us to fit models with and without data from 
those times. These outliers likely represented novel semen exposures possibly resulting from 
unreported acts of vaginal intercourse or from other sexual exposures that would not 
typically be expected to result in PSA or Yc DNA positivity (e.g., use of sex toys, which 
some couples reported). The potential for testing positive for a semen biomarker due to 
sexual exposures other than vaginal sex merits additional exploration. Despite employing 
study procedures attempting to control the female participants' exposure to semen during the 
study cycles and to collect swabs in a standard manner, the study is limited by its reliance on 
participant adherence to study instructions.
The study also was limited by a relatively small sample size. A larger sample size likely 
would have yielded narrower 95% CIs surrounding our predicted sensitivities of positive 
biomarker results. Nevertheless, our results were sufficiently precise for us to comment on 
the relative advantages of the two biomarkers.
Strengths of this research include its controlled aspects in terms of the precise quantities of 
semen inserted and the specific intervals for specimen collection. Also, measuring the two 
biomarkers from the same specimen reduced the risk of observing differences attributable to 
variations in specimen collection procedures. Although we did not explicitly consider how 
individual-level factors (e.g., hormonal influences or inflammation) might affect biomarker 
residence in the vagina, our mixed-effects models took these into account, in large part 
adjusting for the wide interparticipant variability that we would expect for these factors.
Although PSA and Yc DNA are both biomarkers of semen exposure, they measure different 
biological phenomena (presence of seminal fluid and spermatozoa, respectively). They also 
have different strengths and weaknesses as indicators of recent sexual activity. Researchers 
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who seek to incorporate biomarkers of semen exposure into studies should consider 
carefully the amount of exposure they wish to detect (e.g., a study of condom failure would 
need to be capable of detecting small amounts of semen), rates of biomarker decay and 
predicted sensitivities of biomarker positivity at different time points. For example, studies 
evaluating the effectiveness of condoms have compared PSA concentrations detected in pre- 
and postcoital vaginal swabs [16,20,21]. These studies benefitted from a biomarker that is 
detected consistently in specimens collected immediately following potential exposure. In 
other studies, though, the ideal biomarker might need to be consistently and reliably 
detectable for several days. The biomarkers also differ in their costs, with the estimated cost 
per assay for Yc DNA testing being higher than that for PSA. The present study findings 
suggest that PSA may be more consistent as a marker of very recent exposure and that Yc 
DNA may have greater longevity in the vagina, although both markers appear to be 
unreliable indicators of exposure after 24 h, highlighting the need for a marker of semen 
exposure covering a longer time span.
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Fig. 1. 
Decay of PSA by semen dose and time since exposure. *Decay curves are estimated by 
fitting a linear mixed-effects model and using nonparametric smoothing splines.
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Fig. 2. 
Decay of Yc DNA by semen dose and time since exposure. *Decay curves are estimated by 
fitting a linear mixed-effects model and using nonparametric smoothing splines.
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Fig. 3. 
Predicted sensitivity of detecting biomarker by semen dose and time since exposure.
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